Human T-cell leukemia virus type 1 Tax relieves repression of proliferating cell nuclear antigen gene expression.
Human T-cell leukemia virus type 1 (HTLV-1) is the etiological agent of adult T-cell leukemia. The transforming ability of Tax, the viral oncoprotein, is believed to depend on interactions with cell cycle regulators and on transactivation of genes that control cellular proliferation, including proliferating cell nuclear antigen (PCNA), a cofactor associated with DNA replication and repair. Tax associates with cellular transcription factors to alter their affinity for cognate DNA elements, leading to increased or decreased transcription from that promoter. Although it has been demonstrated that Tax transactivates the PCNA promoter, the mechanism of transcriptional activation is unknown. Here we report a cellular complex that binds specifically to a novel site within the minimal Tax-responsive element of the TATAA-less PCNA promoter. Mutation at this binding site or Tax expression inhibited complex formation and increased promoter activity, suggesting that the complex is a transcriptional repressor. The activation of PCNA gene expression by Tax and consequential decrease in nucleotide excision repair mediated by PCNA overexpression could contribute to the reduced DNA repair capacity and genomic instability observed in HTLV-1-infected cells.
Edwards
Dustin C
DC
Department of Molecular Virology and Microbiology, Baylor College of Medicine, MS-385, One Baylor Plaza, Houston, TX 77030, USA.
Marriott
Susan J
SJ
D002460:Cell Line; D004260:DNA Repair; D016356:Gene Products, tax / Q000502:physiology*; D006801:Humans; D009154:Mutation; D018809:Proliferating Cell Nuclear Antigen / Q000235:genetics*; D011401:Promoter Regions, Genetic; D020218:Response Elements; D015533:Transcriptional Activation
D016356:Gene Products, tax; D018809:Proliferating Cell Nuclear Antigen; C514970:tax protein, Human T-lymphotrophic virus 1
J Long Term Eff Med Implants. 2003;13(2):127-40
14510286
J Virol. 2007 Dec;81(23):13075-81
17898074
Lancet. 1986 May 3;1(8488):1031-2
2871307
Cancer Res. 2002 Jun 15;62(12):3562-71
12068005
J Virol. 1997 Feb;71(2):1181-90
8995640
J Biol Chem. 2000 Nov 17;275(46):35926-31
10931836
Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80
7031654
EMBO J. 1993 Nov;12(11):4269-78
8223437
Biochem Biophys Res Commun. 2005 Sep 30;335(3):826-31
16099430
AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1695-700
11080812
J Biol Chem. 2007 Feb 16;282(7):4277-4287
17158882
EMBO J. 1996 Jun 17;15(12):3105-16
8670811
Curr Opin Ophthalmol. 2003 Dec;14(6):420-5
14615649
J Virol. 1999 May;73(5):4299-304
10196328
Lancet. 1985 Aug 24;2(8452):407-10
2863442
Int J Hematol. 1997 Oct;66(3):257-78
9401272
Oncogene. 2005 Sep 5;24(39):6026-34
16155609
AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1623-7
11080801
J Virol. 2007 Jun;81(11):6089-98
17376895
Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10000-5
17548813
Lancet. 1987 Jul 18;2(8551):159
2885620
Oncogene. 2005 Sep 5;24(39):5938-51
16155601
Nucleic Acids Res. 1995 Sep 25;23(18):3732-41
7479004
J Biol Chem. 1999 May 28;274(22):15433-9
10336433
Oncogene. 2005 Sep 5;24(39):5986-95
16155605
J Biol Chem. 1995 May 5;270(18):10976-81
7738039
J Virol. 2006 Jul;80(13):6657-68
16775353
Genes Dev. 1990 Nov;4(11):1875-85
2276622
J Biol Chem. 2005 Feb 18;280(7):6222-30
15574413
Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5
6979048